OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S.

New perfusion technologies and AI-driven controls are accelerating adoption across commercial biologics manufacturing.

TheFly reported on July 6 that Evercore ISI analyst Daniel Markowitz reduced the price target on TMDX to $90 from $100 while ...

TheFly reported on June 29 that Leerink Partners characterized the FDA’s premarket approval of LungFX for UTHR as a positive ...

Clinical guidelines support lower blood pressure targets and active volume removal to mitigate fluid overload in older sepsis ...

Penumbra, Inc. announced the initiation of its FORWARD study, which will collect safety and efficacy data on mechanical ...

TransMedics Group TMDX recently completed its strategic investment in Germany-based PAD Aviation service GmbH, marking a key ...

StrategicinvestmentinGermany-basedPADAviation,apremierEuropeanprivateaviationoperator,laysthefoundationfor TransMedics to establish a dedicated organ transplantation air logistics network acrossEurope ...

Baek, a 35-year-old manager at the South Korean semiconductor titan SK Hynix, was enrolled in a matchmaking company a year ...

A man with a prior below-knee amputation develops progressive stump pain, and vascular imaging reveals an unexpected arterial blockage that is still treatable.

It might mean the eyes could still see when transplanted into the recipient, say the scientists behind the work.

Led by CEO Harry Rowland, VahatiCor is developing the A-Flux coronary sinus reducer implant for coronary microvascular dysfunction.